Online inquiry

IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11021MR)

This product GTTS-WQ11021MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&CLEC12A gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_001207010.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 160364
UniProt ID P07766; Q5QGZ9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11021MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8058MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ13121MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ3494MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ12291MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ13520MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ16018MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ3903MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ14046MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aLAG367
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW